Compare Norwegian Cruise Line Holdings Ltd (NCLH) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norwegian Cruise Line Holdings Ltd vs Novartis AG — how do they compare? Norwegian Cruise Line Holdings Ltd trades at $15.57 (market cap $7.11B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 37.8× Norwegian Cruise Line Holdings Ltd's market cap, and Novartis AG pays a 3.31% dividend while Norwegian Cruise Line Holdings Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Norwegian Cruise Line Holdings Ltd for 68 Days and Novartis AG for 82 Days on average.
| NCLH | NVS | |
|---|---|---|
Market Cap | $7.11B | $268.57B |
Volume | 22,683,268 | 1,532,573 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.02 | $168.62 |
52-Week Low | $14.12 | $121.80 |
Typical Hold Time | 68 Days | 82 Days |
Enterprise Value | $21.93B | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norwegian Cruise Line Holdings (NCLH) trades at $15.49, up 2.92% with bullish technical signals and strong earnings beats. The company shows improving fundamentals with $9.83B revenue in 2025 and net income of $423M, while maintaining attractive valuation metrics including a 9.39 P/E ratio. Recent news highlights management's expectation for Q3 2026 results to exceed guidance, driven by better-than-expected revenue performance.
NCLH presents a compelling investment case with analyst consensus pointing to 35% upside to the $20.86 price target. However, investors face risks from persistent yield pressure, high debt levels ($11.78B long-term debt), and competitive Caribbean pricing. The stock's outlook remains positive given consecutive earnings beats and management's pricing strategies to stabilize performance through 2027.
NVS trades at $143.11, down 0.12% on the day, with a bearish technical signal and mixed earnings history including a recent Q1 2026 miss. The company maintains strong profitability with a 22.5% net income margin and 30.55% ROE, while recent news highlights a major $7.8B licensing deal with China's Abogen and ongoing investor scrutiny following clinical trial setbacks.
The outlook is cautious; analyst consensus is a Hold with a $146 price target, but risks include pipeline disappointments and M&A execution. Upside hinges on successful drug launches and deal integration, while downside stems from competitive pressures and regulatory challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
